AI-generated analysis. Always verify with the original filing.
AIM ImmunoTech Inc. completed its rights offering on March 6, 2026, selling 1,842 units consisting of 1,842 shares of Series G Convertible Preferred Stock and 3,684,000 Class G Warrants for gross proceeds of approximately $1,800,000. The company entered into a Warrant Agency Agreement with Equiniti Trust Company, LLC and filed a Certificate of Designation for the Series G Preferred Stock on March 4, 2026.
Event Type
Disclosure
Mandatory
Variant
8-K
Entry into a Material Definitive Agreement. Warrant Agency Agreement On March 6, 2026, in connection with the closing of its previously announced Rights Offerin
Material Modification to Rights of Security Holders. The disclosure contained in Item 5.03 of this report is incorporated by reference herein. Item 5.03 Amendme
Other Events. On March 6, 2026, the Company completed its previously announced rights offering (the “ Rights Offering ”) pursuant to its effective registration
Financial Statements and Exhibits. Exhibit No. Description 1.1 Dealer-Manager Agreement between the Company and Maxim Group, LLC 3.1 Certificate of Designation
Material Agreement